XML 314 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based compensation and stockholders' equity
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Share-based compensation and stockholders' equity Share-based compensation and stockholders' equity
Share-based compensation
The Company’s share-based compensation expense relates to stock options, performance stock options, restricted stock units, performance stock units and liability classified long-term incentive awards. During the three months ended March 31, 2024, the Company granted stock options to purchase 3.7 million shares of common stock and granted performance stock options, subject to market conditions, to purchase 0.8 million shares of common stock. The grants were made under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and the Emergent BioSolutions Inc. Inducement Plan. Additionally, during the three months ended March 31, 2024, the Company granted a long-term incentive award, subject to market conditions, with the option to settle in any combination of cash or shares, which is accounted for as a liability classified award. The performance stock options and the long-term incentive award were valued using Monte Carlo valuation models, and both have a performance period of five years to vest based on the Company’s stock price performance. The long-term incentive award will be revalued at each reporting period until the award is earned or expires. The Company’s other equity awards typically vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the three months ended March 31, 2024, 0.1 million stock options and 0.1 million shares of restricted stock units were forfeited prior to the completion of the applicable vesting requirements or expiration. An immaterial number of performance stock units were forfeited during the three months ended March 31, 2024.
Share-based compensation expense, net of forfeitures was recorded in the following financial statement line items:
Three Months Ended March 31,
20242023
Cost of Commercial Product sales$— $0.1 
Cost of MCM Product sales0.7 1.3 
Cost of Bioservices0.1 0.3 
R&D0.5 0.7 
Selling, general and administrative4.6 4.4 
Total share-based compensation expense$5.9 $6.8 
Stockholders' equity
At-the-Market Equity Offering Facility
The Company may, from time to time, sell up to $150.0 million aggregate gross sales price of shares of its common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under an “at-the-market” equity offering program (the “ATM Program”) that was entered into on May 17, 2023. There were no sales of the Company’s common stock under the ATM Program during the three months ended March 31, 2024. As a result of the delayed filing of certain of the Company’s periodic reports with the SEC in 2023, the Company is not currently eligible to sell any shares under the ATM Program until the Company has timely filed certain periodic reports required under the Securities Exchange Act of 1934 (the “Exchange Act”) for 12 consecutive calendar months. Between the entry into the ATM Program and March 31, 2024, the Company has sold 1.1 million shares of the Company’s common stock for gross proceeds of $9.1 million, representing an average share price of $8.22 per share. As of March 31, 2024, $140.9 million aggregate gross sales price of shares of the Company’s common stock remains available for issuance under the ATM Program. The Company intends to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes.
Accumulated other comprehensive income (loss), net of tax
The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:
Defined Benefit Pension PlanDerivative InstrumentsForeign Currency
 Translation Adjustments		Total
Balance at December 31, 2023
$— $— $(5.7)$(5.7)
Other comprehensive income before reclassifications— — 0.2 0.2 
Net current period other comprehensive income— — 0.2 0.2 
Balance at March 31, 2024$— $— $(5.5)$(5.5)
Balance at December 31, 2022
$3.5 $6.2 $(6.6)$3.1 
Other comprehensive loss before reclassifications— (4.4)(0.1)(4.5)
Amounts reclassified from accumulated other comprehensive income— 2.4 — 2.4 
Net current period other comprehensive loss— (2.0)(0.1)(2.1)
Balance at March 31, 2023$3.5 $4.2 $(6.7)$1.0 
The tables below present the tax effects related to each component of other comprehensive income (loss):
Three Months Ended March 31,
20242023
PretaxTax ExpenseNet of taxPretaxTax ExpenseNet of tax
Derivative instruments— — — (2.6)0.6 (2.0)
Foreign currency translation adjustments0.2 — 0.2 (0.1)— (0.1)
Total adjustments$0.2 $— $0.2 $(2.7)$0.6 $(2.1)